NCI to Conduct Phase 2 Clinical Trial for Metastatic Triple-Negative Breast Cancer, Combining Personalized Vaccine with Durvalumab and Tremelimumab
A New Horizon in the Treatment of Metastatic Triple-Negative Breast Cancer
Metastatic triple-negative breast cancer (mTNBC) is a difficult-to-treat disease with limited targeted therapy options due to its receptor-negative nature. Currently, treatments include Trodelvy from Gilead Sciences or a combination therapy with Keytruda from Merck, but there is an urgent need for new breakthroughs to overcome resistance. To address this, the U.S. National Cancer Institute (NCI) has planned a unique combination therapy clinical trial, NCT03606967. This Phase 2 trial demonstrates a sophisticated strategy that goes beyond blocking immune evasion by cancer cells, focusing on personalized treatment.
Combining Dual Immune Checkpoint Inhibitors and Chemotherapy
This trial is based on durvalumab (Imfinzi), an anti-PD-L1 immune checkpoint inhibitor from AstraZeneca (AZN), and tremelimumab (Imjudo), an anti-CTLA-4 immune checkpoint inhibitor. In addition, nab-paclitaxel (Abraxane), a standard chemotherapy agent from Bristol Myers Squibb (BMS), is combined to promote cancer cell death. Furthermore, poly-ICLC (Hiltonol) from Oncovir, an immune-enhancing agent, is added to maximize T-cell activation. This multi-target combination therapy aims to block the various pathways that cancer cells use to evade immune surveillance.
The Technology Behind Personalized Neoantigen Vaccines
At its core is a tumor-specific neoantigen (TSNA)-based synthetic long peptide (SLP) vaccine, utilizing next-generation sequencing (NGS) technology. This represents the pinnacle of precision medicine, decoding a patient's unique tumor mutation information to synthesize the optimal neoantigens. Unlike conventional, uniform treatments, this approach trains the patient's immune system to precisely target their own cancer cells. This is considered a groundbreaking alternative that can address the unmet needs of patients who are resistant to existing immune checkpoint inhibitors.
Phase 2 Trial Design and Key Evaluation Metrics
The trial will be conducted with a randomized design, comparing a treatment group and a control group. Group 1 will receive chemotherapy and dual immune checkpoint inhibitors, along with a personalized vaccine, while Group 2 will receive the triple combination therapy without the vaccine. The primary endpoint is progression-free survival (PFS), and secondary endpoints include overall objective response rate (ORR) and overall survival (OS). Patient recruitment is currently underway, and the key focus is on obtaining data demonstrating improved survival rates with the addition of the vaccine.
Commercial Value and Challenges to Overcome
The global mTNBC market is projected to grow to over $2.35 billion by 2032, making it a high-value market. However, personalized vaccines require an average of several weeks for genetic analysis and vaccine production, making production speed and cost reduction critical for commercialization. Standardizing the manufacturing process and demonstrating cost-effectiveness will be essential for securing insurance coverage and market acceptance. If the clinical results are positive, it could trigger large-scale partnerships and technology transfers with multinational pharmaceutical companies.
This Phase 2 clinical trial is a highly significant milestone in verifying the therapeutic efficacy of personalized neoantigen vaccines in the metastatic triple-negative breast cancer (mTNBC) market, which is projected to grow rapidly to approximately $2.35 billion by 2032. In the short term, the key evaluation will be whether AstraZeneca's immune checkpoint inhibitor combination, durvalumab and tremelimumab, demonstrates statistically superior progression-free survival (PFS) compared to Merck's existing standard therapy of Keytruda and chemotherapy. In the medium to long term, this trial will serve as a testbed to determine whether the synthetic long peptide (SLP) technology, which targets patient-specific tumor neoantigens, can establish itself as the next-generation standard combination platform for patients with refractory solid tumors who have failed existing immunotherapies. Ultimately, the key to determining the long-term market landscape will be overcoming logistical challenges, such as shortening the vaccine manufacturing process and establishing a large-scale production system to reduce costs, and translating clinical data into actual commercial value and securing major partnerships.
Source: ClinicalTrials.gov (api_ct)